Skip to Content

News

The UK Medicines and Healthcare Products Regulatory Agency said on November 4 it had authorized Merck and Ridgeback Biotherapeutics' oral antiviral

UK becomes first to authorize Merck and Ridgeback Biotherapeutics’ antiviral molnupiravir to treat mild-to-moderate Covid-19

By Jamie Gumbrecht, CNN The UK Medicines and Healthcare Products Regulatory Agency said Thursday it had authorized Merck and Ridgeback Biotherapeutics’ oral antiviral, molnupiravir, to treat mild-to-moderate Covid-19 in adults at risk for severe illness. It is the world’s first oral antiviral to be authorized anywhere for the treatment of Covid-19. The drug comes in

Continue Reading